Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Psychiatria Polska

[Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
Dominik Strzelecki
Jolanta Rabe-Jabłońska

キーワード

概要

The Glutamatergic system is the most important excitatory system of the human brain. Dysfunction of this system plays an important role in the pathogenesis of numerous psychiatric disorders, including schizophrenia. According to the glutamatergic hypothesis of schizophrenia augmentation of the antipsychotic treatment with glycine--a coagonist of NMDA receptor helps to achieve better improvement.

OBJECTIVE

The aim of the study was to assess changes in mental status i.e. positive, negative and general psychopathology symptoms during augmentation of antipsychotic treatment with glycine in schizophrenic patients in a stable mental state with predominant negative symptoms.

METHODS

The study group consisted of 29 patients with a diagnosis of schizophrenia (ICD-10) with predominant negative symptoms. It was a 10-week prospective open-label study, which included 7 visits. Participants enrolled to the study received a fixed dose of antipsychotic drugs for at least 3 months prior to application of glycine. In addition to the existing antipsychotic treatment, patients were administered glycine orally (up to 60 g/day) for 6 weeks. 2 weeks before and after application of glycine, their mental status was also evaluated. At each visit we assessed severity of schizophrenia symptoms using PANSS.

RESULTS

After 6 weeks of glycine administration we observed statistically significant improvement in positive (PANSS P subscale, -7.8%, p < 0.05), negative symptoms (N subscale, -16.1%, p < 0.001), general psychopathology (G subscale, -12.2%, p < 0.001) and PANSS total score (T, -12.8%, p < 0.001). 2 weeks after the end of glycine augmentation mental status remained stable.

CONCLUSIONS

In the course of treatment with glycine, moderate improvement in negative, positive and general psychopathology symptoms was observed. Use of glycine was safe and well tolerated. Side effects involved gastrointestinal complaints--mainly nausea and vomiting.

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge